UK’s MHRA: Your Blueprint for De-Risking AI Health Investments
In healthcare AI, it’s not just about innovation anymore. It’s about regulatory clarity. If you’re building an AI health tool without a defined Software as…
In healthcare AI, it’s not just about innovation anymore. It’s about regulatory clarity. If you’re building an AI health tool without a defined Software as…
The way the European market handles AI health tools is just different. A notified body is your gatekeeper to market access, full stop. This framework,…
AI health regulation isn’t a single, well-defined path. It’s a mess of overlapping turf wars between different agencies. For legal and compliance leaders in genomics…
Real AI governance in health doesn’t live in white papers. You find it in the guts of a quality management system (QMS), where all the…
The distinction between an AI governance statement and a demonstrable governance system can be stark. For clinical AI vendors, this difference directly translates into regulatory…
The increasing convergence of health data privacy and medical device regulation presents a critical juncture for AI health tools. Companies operating in this space, particularly…
The path to market for AI health tools in Europe increasingly hinges on a single, critical gatekeeper: the Notified Body. For companies working through the…
The field of AI health regulation is a dynamic one, where national bodies often signal broader international trends. For policy analysts tracking these shifts, observing…
The European Union’s Medical Device Regulation (MDR EU Regulation) presents a distinct challenge for AI health tools, one that demands a separate, parallel evidence file…
The establishment of a dedicated review center at the FDA for adaptive AI products marked a key shift, not by loosening regulatory oversight, but by…